IU collaboration to develop computational model of acetaminophen-induced liver failure

December 04, 2014

BLOOMINGTON and INDIANAPOLIS, Ind. -- Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure -- the leading cause of liver failure in the United States -- by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal.

James A. Glazier, director of IU's Biocomplexity Institute and a professor of physics in IU Bloomington's College of Arts and Sciences; James Klaunig, an environmental health professor in the IU School of Public Health-Bloomington; and IU School of Medicine professor of nephrology Kenneth Dunn will work together to develop computational biology models of liver toxicity. The research is considered by the National Institutes of Health as a first step in the development of new technologies capable of predicting the toxicity of therapeutic agents and environmental toxins while simultaneously reducing the use of animals in toxicity studies.

While funding is being provided through the NIH, the research is an outgrowth of a consortium of six federal agencies called the Interagency Modeling and Analysis Group that are working together to promote scientific partnerships focused on increasing the impacts of multiscale modeling.

Multiscale modeling uses mathematics and computation to quantitatively represent and simulate a system at more than one scale while functionally linking the mathematical models across scales that range from molecular, cellular and tissue to organ, whole-body and population.

The models can be designed to integrate diverse data; create testable hypotheses leading to new investigations; identify and share gaps in knowledge; uncover biological mechanisms; or make predictions about clinical outcome or intervention effects. NIH believes the ultimate goal is being able to make realistic scientific predictions to address problems and issues in the environment and in the human body.

"Multiscale models of biological and behavioral systems can be used as important tools to address a range of biomedical, biological, behavioral, environmental and clinical problems," Glazier said. "And they inherently provide a fundamental infrastructure for understanding and predicting biological and environmental processes, diseases, and human and organizational behavior patterns and outcomes."

Understanding liver toxicity could be the key to also understanding the toxicity of drugs and environmental pollutants. If this computational biology modeling effort succeeds, it could pave the way for additional multiscale models being used to prevent, diagnose and treat other diseases or aberrations in normal development, and to predict treatment outcomes.

The three researchers will each lead teams -- two focusing on experimentation and one on modeling -- that together bring multidisciplinary expertise in computation biology (Glazier), advanced microscopic imaging techniques (Dunn) and extensive chemical and biological expertise in pharmacology and toxicology (Klaunig).

They said they chose to simulate the liver because it is a key organ in many toxicological, pharmacological, normal and disease processes; and use acetaminophen as the organ's toxic challenge as it is the most widely used over-the-counter pain reliever and fever reducer in the U.S., with over 25 billion doses sold annually. Available over-the-counter in the U.S. since 1960, acetaminophen is a frequent component in many over-the-counter and prescription combinations with decongestants, antihistamines, sleeping aids and other analgesics such as oxycodone, hydrocodone, dilaudid and codeine.
The research, including computer simulations calibrated using microscopic imaging in the liver of a living mouse, will be conducted at IU laboratories in both Bloomington and Indianapolis. Federal agencies in addition to NIH that are participating in the Interagency Modeling and Analysis Group funding the work include the National Science Foundation, the Food and Drug Administration, the National Aeronautical and Space Administration, the Department of Defense and the Department of Energy.

Indiana University

Related Liver Failure Articles from Brightsurf:

Eating less suppresses liver cancer due to fatty liver
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan.

Surprising players in acute liver failure point to potential treatment
Gut microbes and host cells jointly contribute to the progression of this mostly incurable disease.

Liver fibrosis tied to specific heart failure, regardless of HIV or hepatitis C status
While there is an association between liver fibrosis and heart failure, the mechanisms for this association are currently unclear but may be of particular importance for people living with human immunodeficiency virus (HIV) and/or hepatitis C, both of which are chronic infections that affect the liver and heart.

Study shows artificial intelligence can detect language problems tied to liver failure
Natural language processing, the technology that lets computers read, decipher, understand and make sense of human language, is the driving force behind internet search engines, email filters, digital assistants such as Amazon's Alexa and Apple's Siri, and language-to-language translation apps.

Liver transplants could be redundant with discovery of new liver cell
Researchers at King's College London have used single cell RNA sequencing to identify a type of cell that may be able to regenerate liver tissue, treating liver failure without the need for transplants.

Scientists find new therapy target for drug-induced liver failure
Acetaminophen -- a commonly used pain reliever and fever reducer -- is the leading cause of quickly developing, or acute, liver failure in the U.S.

Blocking platelets: A possible option to prevent fatty liver disease and liver cancer
Blood platelets which interact with liver cells and immune cells play a major role in the development of fatty liver disease, non-alcoholic fatty liver inflammation and liver cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg and from Zurich University and University Hospital have now shown in a publication.

Liver transplants double for alcohol-related liver disease
The proportion of US liver transplants for alcohol-associated liver disease (ALD) has doubled in the last 15 years, in part due to broader acceptance of waiving the mandated period of sobriety before transplants for this population, according to a study by researchers at UC San Francisco, which showed ongoing regional geographic variations in liver transplant rates for ALD patients, whose long-term survival rate is slightly lower than other liver transplant patients.

Liver transplant for alcohol-related liver disease in US
The proportion of liver transplants in the United States for alcohol-associated liver disease increased between 2002 and 2016, with much of the increase associated with a decrease in liver transplant for hepatitis C virus infection because of antiviral therapy.

Real-time detection of cholesterol in liver-on-chip cultures of human liver cells
In a paper to be published in the September/December 2019 issue of TECHNOLOGY, a team of researchers from the IIT, Chicago, has developed a novel microfluidic device for measuring in real-time the cholesterol secreted from liver tissue-chip containing human hepatocytes.

Read More: Liver Failure News and Liver Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.